NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Cervix
Cervix · 13,490 new · 4,200 deaths (ACS 2026) · mortality 2.1 per 100k · 5-yr RS 68.8% (SEER)
Mortality 2.1 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.6% among women (SEER Stat Facts). 305,284 women living with cervical cancer in 2023.
305,284 women living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 50 · at death 60 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence women 7.7 per 100k · mortality women 2.1 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among women aged 35–44. Deaths highest among women aged 55–64. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases stable (2014–2023). Death rates falling 0.7% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Hispanic women 10.1 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native women 3.0 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | — | 10.1 | — | 2.3 |
| Non-Hispanic American Indian/Alaska Native | — | 9.8 | — | 3.0 |
| Non-Hispanic Asian/Pacific Islander | — | 5.9 | — | 1.6 |
| Non-Hispanic Black | — | 8.2 | — | 2.9 |
| Non-Hispanic White | — | 6.8 | — | 2.0 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
USPSTF 2018 A · Women 21–65 (cytology / hrHPV schedules) · Cervical cytology ± hrHPV
Encoded on the published track as an eligibility table — not a personal recommendation. USPSTF-cervical-2018
ACS early-detection pointer
ACS 2025 · People with a cervix at average risk · ACS: start at 25 (primary HPV every 5 years preferred). This demo encodes USPSTF 2018 / ACOG starting at 21. Not equivalent.
Cited ACS statement only. Do not claim USPSTF / NCCN equivalence. ACS-early-detection
ACOG screening pointer
ACOG 2026 · Average-risk people with a cervix · ACOG Committee Statement 28 (2026): cytology q3 at 21–29; preferred clinician-collected primary hrHPV q5 at 30–65. This demo encodes USPSTF 2018 / ACOG-class intervals (cytology q3 or hrHPV / co-test q5). Not equivalent as a preferred-modality table.
Cited specialty / payer statement only. Do not claim USPSTF / NCCN equivalence. ACOG-cervical
CMS screening pointer
CMS 2015 · Medicare beneficiaries considering cervical HPV screening · CMS NCD 210.2.1 (effective July 9, 2015): HPV testing once every five years for asymptomatic beneficiaries aged 30–65, in conjunction with the Pap smear, in FDA-approved or cleared CLIA labs. The NCD also notes Medicare covers pelvic exam / Pap at 12- or 24-month intervals based on beneficiary risk category (42 C.F.R. § 410.56); that risk list is not encoded. This demo encodes USPSTF 2018 / ACOG Committee Statement 28 intervals. Not a coverage determination. Not equivalent. Not an HPV vaccination or dose engine.
Cited specialty / payer statement only. Do not claim USPSTF / NCCN equivalence. CMS-NCD-210.2.1
CMS screening pointer
CMS 2006 · Medicare beneficiaries considering Pap smear or pelvic exam · CMS NCD 210.2 (effective June 19, 2006): a screening Pap smear is covered when the beneficiary has not had one during the preceding two years, or more frequently than every two years when the clinician documents high-risk status. The NCD names high-risk categories; that list is not encoded. Screening pelvic examination (including a clinical breast examination) is also a covered benefit subject to frequency limits. Complementary to CMS NCD 210.2.1 HPV testing. This demo encodes USPSTF 2018 / ACOG Committee Statement 28 intervals. Not a coverage determination. Not equivalent. Not a high-risk scoring engine.
Cited specialty / payer statement only. Do not claim USPSTF / NCCN equivalence. CMS-NCD-210.2
Surveillance pointer
ACOG-cervical 2018 · empty on purpose · USPSTF 2018 / ACOG publish screening intervals. Abnormal-cytology management is not encoded.
Named public source only. Not a personal follow-up calendar. ACOG-cervical
Surveillance pointer
ACS-cervix-follow 2025 · cited only · ACS living-as-a-survivor page names close follow-up after cervical-cancer treatment with exams, lab tests, or imaging. Those months are not encoded. Complementary to the empty-on-purpose abnormal-cytology pointer. Not an ASCCP management engine.
Named public source only. Not a personal follow-up calendar. ACS-cervix-follow
Surveillance pointer
ACS-cervix-follow 2025 · cited only · ACS living-as-a-survivor page names second cancers after cervical-cancer treatment, including HPV-linked and radiation-linked sites. Those named sites are not encoded. Complementary to the empty-on-purpose first pointer and the ACS living-as row. Not an HPV-dose, anal-Pap, or ASCCP engine. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-cervix-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names low estrogen after oophorectomy, pelvic radiation, or hormone-blocking medicines, plus osteopenia or osteoporosis and lymphedema after node surgery or radiation. Those names are not encoded. Complementary to the empty-on-purpose first pointer and the ACS living-as / second-cancer rows. Not a DXA-interval, hormone, HPV-dose, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical screening may be named. Those plans and screens are not encoded. Complementary to the GYN printout. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not an HPV-dose, anal-Pap, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACOG-cervical cited · empty on purpose · Cervix-treatment toxicity is not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACOG-cervical
Toxicity pointer
ACS-cervix-follow 2025 · empty on purpose · ACS living-as-a-survivor page names treatment side effects that may last or appear later. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-cervix-follow
Toxicity pointer
ACS-cervix-follow 2025 · empty on purpose · ACS living-as-a-survivor page names later cancers after cervical-cancer treatment. Those second-cancer risks are not encoded. Complementary to the empty-on-purpose first pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-cervix-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later low estrogen, osteoporosis, and lymphedema after pelvic treatment or node surgery. Those late effects are not encoded. Complementary to the empty-on-purpose first pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Regular cervical screening may be named. Those named tests are not encoded. Complementary to the GYN printout. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — GYN
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, nausea, and vaginal or vulvar field irritation. Late: radiation proctitis and cystitis, incontinence, fistula, menopause symptoms, fertility effects, low estrogen, osteoporosis, lymphedema, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: pelvic bleeding, pain, or leakage after RT; regular cervical screening may be named; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not a CA-125, HPV-dose, or ASCCP engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Adult GYN RT fields only. Gestational trophoblastic disease is out of domain. Complementary ACS long-term page is named, not encoded. Not a CA-125 or ASCCP engine. No invented trial percent.
Open GYN printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-cervix · guideline-only · evaluateCervix · USPSTF-2018-cervical
SEER 5-year relative survival by stage
Localized 91.8% · Regional 64% · Distant 20.5% · All 68.8%
Cervical cancer. SEER Cancer Stat Facts. Do not map Hodgkin lymphoma onto this table.
Percent of cases by stage (SEER Stat Facts)
Localized 41% · Regional 37% · Distant 16% · Unknown 6%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Female site.
lifetime
Cervix birth-to-death (women)
≈ 0.6%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
interval only — no incidence %ages 30–65: cytology q3 or hrHPV/co-test q5 (USPSTF 2018 / ACOG) · last exam inside the interval
screening
USPSTF 2018 / ACOG interval
Stay on the current interval
on this plan
surveillance
Abnormal cytology / HPV is clinic-directed
Empty on purpose — ASCCP / treatment toxicity not encoded
empty on purpose
toxicity
No cervix-treatment toxicity engine
Empty on purpose — ASCCP / treatment toxicity not encoded
empty on purpose
Noah · Plan — skin cancer
out of domainsex-at-birth is not female in this synthetic fixture
screening
USPSTF 2018 / ACOG interval
out of domain
surveillance
Abnormal cytology / HPV is clinic-directed
Empty on purpose — ASCCP / treatment toxicity not encoded
out of domain
toxicity
No cervix-treatment toxicity engine
Empty on purpose — ASCCP / treatment toxicity not encoded
out of domain
Walter · S1 prostate
out of domainsex-at-birth is not female in this synthetic fixture
screening
USPSTF 2018 / ACOG interval
out of domain
surveillance
Abnormal cytology / HPV is clinic-directed
Empty on purpose — ASCCP / treatment toxicity not encoded
out of domain
toxicity
No cervix-treatment toxicity engine
Empty on purpose — ASCCP / treatment toxicity not encoded
out of domain
Priya · average-risk
interval only — no incidence %ages 30–65: cytology q3 or hrHPV/co-test q5 (USPSTF 2018 / ACOG) · last exam inside the interval
screening
USPSTF 2018 / ACOG interval
Stay on the current interval
on this plan
surveillance
Abnormal cytology / HPV is clinic-directed
Empty on purpose — ASCCP / treatment toxicity not encoded
empty on purpose
toxicity
No cervix-treatment toxicity engine
Empty on purpose — ASCCP / treatment toxicity not encoded
empty on purpose
People without a cervix are out of domain. 2023 prevalence 305,284 women (SEER) is a population count, not a personal risk.